Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.

Nature. 2019 May 29. doi: 10.1038/s41586-019-1252-x. [Epub ahead of print]

PMID:
31142838
2.

HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia.

Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R.

Cancers (Basel). 2019 Apr 23;11(4). pii: E575. doi: 10.3390/cancers11040575.

3.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

4.

Activation of Hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia.

Ghia EM, Rassenti LZ, Neuberg DS, Blanco A, Yousif F, Smith EN, McPherson JD, Hudson TJ, Harismendy O, Frazer KA, Kipps TJ.

Blood. 2019 Mar 28. pii: blood-2018-09-873695. doi: 10.1182/blood-2018-09-873695. [Epub ahead of print]

PMID:
30923040
5.

A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.

Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Ten Hacken E, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L.

Cancer Cell. 2019 Feb 11;35(2):283-296.e5. doi: 10.1016/j.ccell.2018.12.013. Epub 2019 Jan 31.

6.

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.

Hasan MK, Rassenti L, Widhopf GF 2nd, Yu J, Kipps TJ.

Leukemia. 2019 Mar;33(3):653-661. doi: 10.1038/s41375-018-0306-7. Epub 2018 Dec 19.

PMID:
30568170
7.

SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.

Brander DM, Friedman DR, Volkheimer AD, Christensen DJ, Rassenti LZ, Kipps TJ, Guadalupe E, Chen Y, Zhang D, Wang X, Davis C, Owzar K, Weinberg JB.

Br J Haematol. 2019 Feb;184(4):605-615. doi: 10.1111/bjh.15677. Epub 2018 Nov 15.

PMID:
30443898
8.

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ.

JCI Insight. 2018 Oct 4;3(19). pii: 121438. doi: 10.1172/jci.insight.121438.

9.

miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients.

Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y, Croce CM.

Blood. 2018 Nov 15;132(20):2179-2182. doi: 10.1182/blood-2018-04-845115. Epub 2018 Sep 21.

PMID:
30242085
10.

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma.

Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF 2nd, Kipps TJ.

Oncotarget. 2018 May 15;9(37):24731-24736. doi: 10.18632/oncotarget.25340. eCollection 2018 May 15.

11.

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ.

Cell Stem Cell. 2018 Jun 1;22(6):951-959.e3. doi: 10.1016/j.stem.2018.05.018.

12.

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.

Hasan MK, Yu J, Widhopf GF 2nd, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ.

Blood. 2018 Jul 12;132(2):170-178. doi: 10.1182/blood-2017-12-819383. Epub 2018 Apr 20.

13.

MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia.

Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF 2nd, Kipps TJ, Croce CM.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10731-10736. doi: 10.1073/pnas.1708264114. Epub 2017 Sep 18.

14.

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.

Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE.

J Hematol Oncol. 2017 May 19;10(1):112. doi: 10.1186/s13045-017-0435-x.

15.

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.

Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, Shen Z, Briggs SP, Kipps TJ.

Leukemia. 2017 Dec;31(12):2615-2622. doi: 10.1038/leu.2017.133. Epub 2017 May 3.

16.

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.

Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, Wu R, Rassenti LZ, Widhopf GF, Shen Z, Briggs SP, Kipps TJ.

Leukemia. 2017 Dec;31(12):2608-2614. doi: 10.1038/leu.2017.132. Epub 2017 May 3.

17.

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.

Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Coombes KR, Hertlein EK.

Oncotarget. 2017 Apr 18;8(16):25942-25954. doi: 10.18632/oncotarget.15401.

18.

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR.

Leukemia. 2017 Jun;31(6):1348-1354. doi: 10.1038/leu.2017.34. Epub 2017 Jan 24.

19.

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.

Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, Zhang L, Rassenti LZ, Widhopf Ii GF, Kipps TJ.

Leukemia. 2017 Jun;31(6):1333-1339. doi: 10.1038/leu.2016.368. Epub 2016 Dec 1.

20.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F.

Leukemia. 2017 Jul;31(7):1547-1554. doi: 10.1038/leu.2016.359. Epub 2016 Nov 28.

PMID:
27890934
21.

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.

Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ.

Cancer Cell. 2016 Nov 14;30(5):750-763. doi: 10.1016/j.ccell.2016.10.005. Epub 2016 Nov 3.

22.

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ.

Blood. 2016 Dec 22;128(25):2931-2940. doi: 10.1182/blood-2016-04-712562. Epub 2016 Nov 4.

23.

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA.

Br J Haematol. 2018 Feb;180(4):597-600. doi: 10.1111/bjh.14398. Epub 2016 Oct 21. No abstract available.

PMID:
27766619
24.

Selectivity in Small Molecule Splicing Modulation.

Kumar D, Kashyap MK, La Clair JJ, Villa R, Spaanderman I, Chien S, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE.

ACS Chem Biol. 2016 Oct 21;11(10):2716-2723. Epub 2016 Aug 8.

PMID:
27499047
25.

Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.

Amaya-Chanaga CI, Rassenti LZ.

Best Pract Res Clin Haematol. 2016 Mar;29(1):79-89. doi: 10.1016/j.beha.2016.08.005. Epub 2016 Aug 10. Review.

PMID:
27742074
26.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR.

Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.

27.

Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations.

Manouchehri S, Ibsen S, Wright J, Rassenti L, Ghia EM, Widhopf GF 2nd, Kipps TJ, Heller MJ.

Int J Hematol Oncol. 2016 May;5(1):27-35. doi: 10.2217/ijh-2015-0009. Epub 2016 May 5.

28.

Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer.

Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps TJ, Liu CG, Croce CM.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5071-6. doi: 10.1073/pnas.1604266113. Epub 2016 Apr 11.

29.

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S.

Blood Cancer J. 2016 Mar 11;6:e404. doi: 10.1038/bcj.2016.9.

30.

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.

Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps TJ, Kay NE.

Br J Haematol. 2016 Apr;173(1):105-13. doi: 10.1111/bjh.13933. Epub 2016 Feb 5.

31.

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.

Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C.

Nat Genet. 2016 Mar;48(3):253-64. doi: 10.1038/ng.3488. Epub 2016 Jan 18.

32.

Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.

Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE.

Oncotarget. 2016 Jan 19;7(3):2809-22. doi: 10.18632/oncotarget.6465.

33.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.

Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.

34.

Quaking and miR-155 interactions in inflammation and leukemogenesis.

Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, Richmond T, Kim T, Sheetz T, Sun HL, Lagana A, Veneziano D, Volinia S, Rassenti L, Kipps T, Awad H, Michaille JJ, Croce CM.

Oncotarget. 2015 Sep 22;6(28):24599-610. doi: 10.18632/oncotarget.5248.

35.

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.

Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA.

EBioMedicine. 2015 Apr 29;2(6):572-82. doi: 10.1016/j.ebiom.2015.04.018. eCollection 2015 Jun.

36.

Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.

Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, Jones H, Ghia EM, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE.

Haematologica. 2015 Jul;100(7):945-54. doi: 10.3324/haematol.2014.122069. Epub 2015 Apr 10.

37.

Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development.

Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, Matsui H, Rozenzhak S, Alakus H, Shepard PJ, Dai Y, Khosroheidari M, Bina M, Gunderson KL, Messer K, Muthuswamy L, Hudson TJ, Harismendy O, Barrett CL, Jamieson CH, Carson DA, Kipps TJ, Frazer KA.

Blood Cancer J. 2015 Apr 10;5:e303. doi: 10.1038/bcj.2015.14.

38.

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.

Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, Byrd JC.

Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4322-7. doi: 10.1073/pnas.1503587112. Epub 2015 Mar 18.

39.

Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers.

DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, Jamieson CH, Carson D, Kipps TJ, Frazer KA.

PLoS Comput Biol. 2015 Mar 13;11(3):e1004105. doi: 10.1371/journal.pcbi.1004105. eCollection 2015 Mar.

40.

TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.

Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2169-74. doi: 10.1073/pnas.1500010112. Epub 2015 Feb 2.

41.

Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.

Kämpjärvi K, Järvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, Dufva O, Kontro M, Rassenti L, Hertlein E, Kipps TJ, Porkka K, Byrd JC, de la Chapelle A, Vahteristo P.

Oncotarget. 2015 Jan 30;6(3):1884-8.

42.

Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments.

Smith EN, Jepsen K, Khosroheidari M, Rassenti LZ, D'Antonio M, Ghia EM, Carson DA, Jamieson CH, Kipps TJ, Frazer KA.

Genome Biol. 2014 Aug 7;15(8):420. doi: 10.1186/s13059-014-0420-4.

43.

MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ.

Blood. 2014 Jul 24;124(4):546-54. doi: 10.1182/blood-2014-03-559690. Epub 2014 Jun 9.

44.

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.

Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC.

Blood. 2014 Jul 3;124(1):42-8. doi: 10.1182/blood-2014-02-555722. Epub 2014 May 27. Erratum in: Blood. 2014 Sep 11;124(11):1848.

45.

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ.

J Clin Oncol. 2014 Jul 1;32(19):2067-73. doi: 10.1200/JCO.2013.51.5890. Epub 2014 May 27.

46.

Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene.

Acunzo M, Romano G, Wernicke D, Balatti V, Rassenti LZ, dell'Aquila M, Kipps TJ, Pekarsky Y, Croce CM.

Blood. 2014 Jul 10;124(2):259-62. doi: 10.1182/blood-2014-02-554675. Epub 2014 May 22.

47.

Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.

Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps TJ, Gribben JG.

Blood. 2014 Jun 26;123(26):4101-10. doi: 10.1182/blood-2014-01-552307. Epub 2014 May 14.

48.

miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.

Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ.

Blood. 2014 Jul 3;124(1):84-95. doi: 10.1182/blood-2013-09-527234. Epub 2014 May 1.

49.

Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.

Veronese A, Pepe F, Chiacchia J, Pagotto S, Lanuti P, Veschi S, Di Marco M, D'Argenio A, Innocenti I, Vannata B, Autore F, Marchisio M, Wernicke D, Verginelli F, Leone G, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R.

Leukemia. 2015 Jan;29(1):86-95. doi: 10.1038/leu.2014.139. Epub 2014 Apr 15.

50.

Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma.

Sonnenberg A, Marciniak JY, Skowronski EA, Manouchehri S, Rassenti L, Ghia EM, Widhopf GF 2nd, Kipps TJ, Heller MJ.

Electrophoresis. 2014 Jul;35(12-13):1828-36. doi: 10.1002/elps.201400016. Epub 2014 May 14.

Supplemental Content

Loading ...
Support Center